<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03270358</url>
  </required_header>
  <id_info>
    <org_study_id>17-AOI-03</org_study_id>
    <nct_id>NCT03270358</nct_id>
  </id_info>
  <brief_title>OStéopontin as a Marker Of StenoSIS - OSMOSIS</brief_title>
  <acronym>OSMOSIS</acronym>
  <official_title>OStéopontin as a Marker Of StenoSIS - OSMOSIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that a plasma protein named osteopontin (OPN) could serve as a biological&#xD;
      predictive marker of acute AVF dysfunction. In several scientific studies, plasma OPN was&#xD;
      correlated with coronary stent restenosis, and with cardiovascular outcome in patients with&#xD;
      diabetes and renal insufficiency. This protein is secreted by several cellular types, like&#xD;
      distal tubule epithelial cells, macrophages, but also fibroblasts and cardiac and vascular&#xD;
      endothelial cells, in response to several specific stimuli. It acts like a cytokine, inducing&#xD;
      immunological mechanisms as well as tissue remodeling.&#xD;
&#xD;
      The main objective of this study is to show that the amount of plasma OPN is higher in&#xD;
      patients presenting with an AVF stenosis, compared with patients with a functioning AVF.&#xD;
&#xD;
      OSMOSIS is a monocentric pilot study that will include patients into two groups during 12&#xD;
      months (no specific follow-up). The control group will include patients that have been&#xD;
      dialyzed on an AVF, in the dialysis center of Nice University Hospital, for at least 3 months&#xD;
      without any incident. The experimental group will include hemodialysis patients hospitalized&#xD;
      in the department of vascular surgery for acute AVF dysfunction, needing endovascular or open&#xD;
      surgical revision for venous stenosis.&#xD;
&#xD;
      Blood will be withdrawn right before dialysis or surgical procedure. Plasma OPN will me&#xD;
      measured by ELISA. Their clinical data would be collected from medical file at the same time.&#xD;
      After the procedure, patients will be followed-up according to usual protocols.&#xD;
&#xD;
      To show a significant difference of 100ng/mL plasma OPN between the two groups, with a power&#xD;
      of 90% and alpha risk of 0.05, we plan to include 76 patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasmatic osteopontin level</measure>
    <time_frame>at inclusion</time_frame>
    <description>Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.&#xD;
Control arm: right before a dialysis session&#xD;
Experimental arm: right before the surgery for stenosis of the fistula</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral plasmatic osteopontin level in the contralateral arm</measure>
    <time_frame>at inclusion</time_frame>
    <description>Peripheral plasmatic osteopontin level (ng/ml) collected in the contralateral arm (to measure the potential bias of a local osteopontin production in the fistula)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral plasmatic osteopontin level in the contralateral arm</measure>
    <time_frame>at inclusion</time_frame>
    <description>Measure of the plasmatic osteopontin specificity and sensibility on the occurrence of a fistula stenosis (differents tresholds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral plasmatic osteopontin level in the contralateral arm</measure>
    <time_frame>at inclusion</time_frame>
    <description>Collection of comorbidity factors (diabetes, arterial hypertension, coronaropathy, overweight (BMI)), clinical factors (age and gender) and treatments at the time of patient's inclusion (anticoagulant, antisludge, antihypertensive drug, statins, erythropoietin)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Stenosis</condition>
  <arm_group>
    <arm_group_label>patient with stenosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient coming to the vascular surgery unit to receive surgery regarding their fistula stenosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patient without stenosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient coming for their dialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling in arterioveinous fistula without stenosis</intervention_name>
    <description>Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.&#xD;
Blood sampling in arterioveinous fistula right before a dialysis session</description>
    <arm_group_label>patient without stenosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling in arterioveinous fistula with stenosis</intervention_name>
    <description>Blood sampling in arterioveinous fistula right before the surgery for stenosis of the fistula</description>
    <arm_group_label>patient with stenosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients under a social security scheme&#xD;
&#xD;
          -  Written informed consent obtain&#xD;
&#xD;
          -  18 years old or older&#xD;
&#xD;
          -  end-stage renal failure disease with 3 months dialysis minimum on a native&#xD;
             arteriovenous fistula&#xD;
&#xD;
        Non-inclusion Criteria:&#xD;
&#xD;
          -  Subject under juridicial protection&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Subject already enrolled in a clinical trial involving a drug or an implantable&#xD;
             medical device&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Withdrawal of consent&#xD;
&#xD;
          -  Investigator or sponsor decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nirvana SADAGHIANLOO</last_name>
    <role>Principal Investigator</role>
    <affiliation>sadaghianloo.n@chu-nice.fr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nirvana SADAGHIANLOO</last_name>
    <phone>0492038548</phone>
    <email>sadaghianloo.n@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie CONTENTI</last_name>
    <email>contenti.j@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Nice - Service de chirurgie vasculaire</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nirvana Sadaghianloo, MD</last_name>
      <phone>04 92 03 38 35</phone>
      <email>sadaghianloo.n@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Julie CONTENTI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>August 30, 2017</study_first_submitted>
  <study_first_submitted_qc>August 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2017</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

